[Meglumine acridonacetate in combined antiviral treatment of HBeAg-positive chronic hepatitis B].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Assot︠s︡iat︠s︡ii︠a︡ delovoĭ pressy Gruzii Country of Publication: Georgia (Republic) NLM ID: 101218222 Publication Model: Print Cited Medium: Internet ISSN: 1512-0112 (Print) Linking ISSN: 15120112 NLM ISO Abbreviation: Georgian Med News Subsets: MEDLINE
    • Publication Information:
      Original Publication: Tbilisi : Nʹi︠u︡-Ĭork : Assot︠s︡iat︠s︡ii︠a︡ delovoĭ pressy Gruzii ; International Academy of Science, Education, Industry & Arts
    • Subject Terms:
      Antiviral Agents/*therapeutic use ; Hepatitis B e Antigens/*immunology ; Hepatitis B virus/*immunology ; Hepatitis B, Chronic/*drug therapy ; Meglumine/*therapeutic use; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Hepatitis B, Chronic/immunology ; Humans ; Interferon-alpha/therapeutic use ; Male ; Middle Aged ; Treatment Outcome ; Young Adult
    • Abstract:
      647 patients with HBeAg positive chronic hepatitis B who have not previously received antiviral therapy were participated in randomized, post-marketing, double-blinded, placebo-controlled clinical trial. Interferon inducer cycloferon was presented as study drug. 323 patients with chronic hepatitis B (HBV) with "wild" HBeAg(+) strain of HBV were treated with cycloferon and Lamivudin for 48 weeks. Control group included 324 patients with similar pathology, treated with Lamivudin and placebo for 48 weeks. The study has shown the benefit of cycloferon+lamivudin treatment in comparison with lamivudin monotherapy. Improving of liver histology in 48 weeks of the therapy was observed in 71% of patients in Study group in comparison with 57% in control group (p<0.01). Combined therapy has resulted in decrease of relapse by 24 week of the follow-up period (13% vs. 86%, p<0.001). The higher efficacy of cycloferon+lamivudin in patients with HBeAg positive chronic hepatitis B has proven the role of own antiviral effect of interferon inducer cycloferon, interferon effect of cycloferon in the elimination of virus-infected hepatocytes, as well as the presence of an immunomodulatory effect of the preparation, aimed at the elimination of HBeAg and HBsAg with the following seroconversion. 48-week course of combined antiviral therapy of HBeAg-positive patients with chronic hepatitis B is recommended as first-line therapy for patients with HBeAg-positive chronic hepatitis B, who have not previously received nucleoside analogues, as well as alternative therapy of Lamivudin-refractory patients.
    • Accession Number:
      0 (Antiviral Agents)
      0 (Hepatitis B e Antigens)
      0 (Interferon-alpha)
      6HG8UB2MUY (Meglumine)
    • Publication Date:
      Date Created: 20130719 Date Completed: 20140204 Latest Revision: 20130718
    • Publication Date:
      20231215
    • Accession Number:
      23863208